HEALTH● LOWJul 23 · Jul 23, 2026, 10:45 AM
Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
CNBC
There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH24m agoLaunch of virtual autopsy at Kozhikode Medical College Hospital likely to take timeThe HinduHEALTH50m agoDuchess Hospital marks five years of giant milestonesPremium TimesHEALTH51m agoPsychology says that when getting to know someone, some people pay attention to details that go beyond first impressions. They observe how they treat others, if they keep their promises, and how they respond when a disagreement or an unexpected situation arises.ClarínHEALTH54m agoWhat to know about new guidance on GLP-1 use during pregnancyCBS News